Comparable effect of aliskiren or a diuretic added on an angiotensin II receptor blocker on augmentation index in hypertension: A multicentre, prospective, randomised study

Toru Miyoshi, Takashi Murakami, Satoru Sakuragi, Masayuki Doi, Seiji Nanba, Atsushi Mima, Youkou Tominaga, Takafumi Oka, Yutaka Kajikawa, Kazufumi Nakamura, Hiroshi Itoh

Research output: Contribution to journalArticle

Abstract

Background The effects of antihypertensive drug combination therapy on central blood pressure (BP) and augmentation index (AI) have not been fully elucidated. We investigated the effects of the direct renin inhibitor, aliskiren, or a diuretic added to an angiotensin II receptor blocker on AI in patients with essential hypertension. Methods A 24-week, prospective, multicentre, randomised, open-label study enrolled 103 patients already treated with valsartan. Participants were randomly allocated to receive either valsartan with aliskiren (V+A), or valsartan with trichlormethiazide (V+T). The primary outcome was the change in AI derived from radial artery tonometry. Secondary outcome measures included systolic and diastolic BP, cardio-ankle vascular index (CAVI, which reflects arterial stiffness) and urinary 8-hydroxydeoxyguanosine concentration. Results After 24 weeks, systolic and diastolic BP were significantly reduced in both groups to a broadly comparable extent. There was no significant difference in AI at the end of the study between the V+A group and the V+T group (between-group difference: -2.3%, 95% CI -6.9% to 2.2%, p=0.31). Central BP at the end of the study also did not differ between the two groups (p=0.62). There was no significant difference in the CAVI between the groups at the end of the study. Urinary 8-hydroxydeoxyguanosine concentration was significantly lower in the V+A group than in the V+T group (p <0.01), suggesting that V+A attenuated oxidative stress more than V+T. Conclusion The combination of valsartan and aliskiren had an effect on AI comparable with that of the combination of valsartan and trichlormethiazide.

Original languageEnglish
Article numbere000591
JournalOpen Heart
Volume4
Issue number1
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Valsartan
Angiotensin Receptor Antagonists
Diuretics
Prospective Studies
Blood Pressure
Hypertension
Trichlormethiazide
Vascular Stiffness
Radial Artery
Manometry
Drug Combinations
Renin
Ankle
Antihypertensive Agents
Blood Vessels
aliskiren
Oxidative Stress
Outcome Assessment (Health Care)
Drug Therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Comparable effect of aliskiren or a diuretic added on an angiotensin II receptor blocker on augmentation index in hypertension : A multicentre, prospective, randomised study. / Miyoshi, Toru; Murakami, Takashi; Sakuragi, Satoru; Doi, Masayuki; Nanba, Seiji; Mima, Atsushi; Tominaga, Youkou; Oka, Takafumi; Kajikawa, Yutaka; Nakamura, Kazufumi; Itoh, Hiroshi.

In: Open Heart, Vol. 4, No. 1, e000591, 01.03.2017.

Research output: Contribution to journalArticle

Miyoshi, Toru ; Murakami, Takashi ; Sakuragi, Satoru ; Doi, Masayuki ; Nanba, Seiji ; Mima, Atsushi ; Tominaga, Youkou ; Oka, Takafumi ; Kajikawa, Yutaka ; Nakamura, Kazufumi ; Itoh, Hiroshi. / Comparable effect of aliskiren or a diuretic added on an angiotensin II receptor blocker on augmentation index in hypertension : A multicentre, prospective, randomised study. In: Open Heart. 2017 ; Vol. 4, No. 1.
@article{3dd809b5cdbb4d1fb30116265ae0a387,
title = "Comparable effect of aliskiren or a diuretic added on an angiotensin II receptor blocker on augmentation index in hypertension: A multicentre, prospective, randomised study",
abstract = "Background The effects of antihypertensive drug combination therapy on central blood pressure (BP) and augmentation index (AI) have not been fully elucidated. We investigated the effects of the direct renin inhibitor, aliskiren, or a diuretic added to an angiotensin II receptor blocker on AI in patients with essential hypertension. Methods A 24-week, prospective, multicentre, randomised, open-label study enrolled 103 patients already treated with valsartan. Participants were randomly allocated to receive either valsartan with aliskiren (V+A), or valsartan with trichlormethiazide (V+T). The primary outcome was the change in AI derived from radial artery tonometry. Secondary outcome measures included systolic and diastolic BP, cardio-ankle vascular index (CAVI, which reflects arterial stiffness) and urinary 8-hydroxydeoxyguanosine concentration. Results After 24 weeks, systolic and diastolic BP were significantly reduced in both groups to a broadly comparable extent. There was no significant difference in AI at the end of the study between the V+A group and the V+T group (between-group difference: -2.3{\%}, 95{\%} CI -6.9{\%} to 2.2{\%}, p=0.31). Central BP at the end of the study also did not differ between the two groups (p=0.62). There was no significant difference in the CAVI between the groups at the end of the study. Urinary 8-hydroxydeoxyguanosine concentration was significantly lower in the V+A group than in the V+T group (p <0.01), suggesting that V+A attenuated oxidative stress more than V+T. Conclusion The combination of valsartan and aliskiren had an effect on AI comparable with that of the combination of valsartan and trichlormethiazide.",
author = "Toru Miyoshi and Takashi Murakami and Satoru Sakuragi and Masayuki Doi and Seiji Nanba and Atsushi Mima and Youkou Tominaga and Takafumi Oka and Yutaka Kajikawa and Kazufumi Nakamura and Hiroshi Itoh",
year = "2017",
month = "3",
day = "1",
doi = "10.1136/openhrt-2017-000591",
language = "English",
volume = "4",
journal = "Open Heart",
issn = "2053-3624",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Comparable effect of aliskiren or a diuretic added on an angiotensin II receptor blocker on augmentation index in hypertension

T2 - A multicentre, prospective, randomised study

AU - Miyoshi, Toru

AU - Murakami, Takashi

AU - Sakuragi, Satoru

AU - Doi, Masayuki

AU - Nanba, Seiji

AU - Mima, Atsushi

AU - Tominaga, Youkou

AU - Oka, Takafumi

AU - Kajikawa, Yutaka

AU - Nakamura, Kazufumi

AU - Itoh, Hiroshi

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background The effects of antihypertensive drug combination therapy on central blood pressure (BP) and augmentation index (AI) have not been fully elucidated. We investigated the effects of the direct renin inhibitor, aliskiren, or a diuretic added to an angiotensin II receptor blocker on AI in patients with essential hypertension. Methods A 24-week, prospective, multicentre, randomised, open-label study enrolled 103 patients already treated with valsartan. Participants were randomly allocated to receive either valsartan with aliskiren (V+A), or valsartan with trichlormethiazide (V+T). The primary outcome was the change in AI derived from radial artery tonometry. Secondary outcome measures included systolic and diastolic BP, cardio-ankle vascular index (CAVI, which reflects arterial stiffness) and urinary 8-hydroxydeoxyguanosine concentration. Results After 24 weeks, systolic and diastolic BP were significantly reduced in both groups to a broadly comparable extent. There was no significant difference in AI at the end of the study between the V+A group and the V+T group (between-group difference: -2.3%, 95% CI -6.9% to 2.2%, p=0.31). Central BP at the end of the study also did not differ between the two groups (p=0.62). There was no significant difference in the CAVI between the groups at the end of the study. Urinary 8-hydroxydeoxyguanosine concentration was significantly lower in the V+A group than in the V+T group (p <0.01), suggesting that V+A attenuated oxidative stress more than V+T. Conclusion The combination of valsartan and aliskiren had an effect on AI comparable with that of the combination of valsartan and trichlormethiazide.

AB - Background The effects of antihypertensive drug combination therapy on central blood pressure (BP) and augmentation index (AI) have not been fully elucidated. We investigated the effects of the direct renin inhibitor, aliskiren, or a diuretic added to an angiotensin II receptor blocker on AI in patients with essential hypertension. Methods A 24-week, prospective, multicentre, randomised, open-label study enrolled 103 patients already treated with valsartan. Participants were randomly allocated to receive either valsartan with aliskiren (V+A), or valsartan with trichlormethiazide (V+T). The primary outcome was the change in AI derived from radial artery tonometry. Secondary outcome measures included systolic and diastolic BP, cardio-ankle vascular index (CAVI, which reflects arterial stiffness) and urinary 8-hydroxydeoxyguanosine concentration. Results After 24 weeks, systolic and diastolic BP were significantly reduced in both groups to a broadly comparable extent. There was no significant difference in AI at the end of the study between the V+A group and the V+T group (between-group difference: -2.3%, 95% CI -6.9% to 2.2%, p=0.31). Central BP at the end of the study also did not differ between the two groups (p=0.62). There was no significant difference in the CAVI between the groups at the end of the study. Urinary 8-hydroxydeoxyguanosine concentration was significantly lower in the V+A group than in the V+T group (p <0.01), suggesting that V+A attenuated oxidative stress more than V+T. Conclusion The combination of valsartan and aliskiren had an effect on AI comparable with that of the combination of valsartan and trichlormethiazide.

UR - http://www.scopus.com/inward/record.url?scp=85015300324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015300324&partnerID=8YFLogxK

U2 - 10.1136/openhrt-2017-000591

DO - 10.1136/openhrt-2017-000591

M3 - Article

AN - SCOPUS:85015300324

VL - 4

JO - Open Heart

JF - Open Heart

SN - 2053-3624

IS - 1

M1 - e000591

ER -